8 Flashcards
Children younger than 5 years are at a greater risk for lead toxicity and its sequela because of ?
increased GI absorption, more frequent hand-to-mouth activity, and a susceptible developing CNS
s/s at high blood lead levels (BLLs)
Anorexia, hyperirritability, altered sleep pattern, and decreased play, abdominal pain, vomiting, constipation, Developmental regression, especially with speech,
signs of encephalopathy in lead poisoning
Persistent vomiting, ataxia, altered consciousness, coma, and seizures
Permanent, long-term consequences of lead poisoning
learning and cognitive deficits and aggressive behavior
lead chelation in an asymptomatic child may consist of ?
IM calcium disodium ethylenediaminetetraacetic acid (CaEDTA) or more commonly oral meso-2,3-dimercaptosuccinic acid (DMSA, succimer)
Hospitalized symptomatic patients with lead poisoning are often treated with
2,3-dimercaptopropanol (British anti-Lewisite [BAL]) and CaEDTA
the CDC identifies children with lead levels above ? as having an elevated lead level and requiring further investigation
5 μg/dL
Chelation therapy is currently advised for patients with a blood lead level of ? and above Environmental investigation is recommended in patients with a blood lead level of ? and above
45 μg/dL
20 μg/dL
Although medications are the most common cause of SJS overall, ? typically account for a higher percentage of cases in children than in adults
infections related to viruses and atypical bacteria, such as M pneumoniae, Herpes viridae
management of SJS
Stop offending agent and admit to the hospital for close observation lab tests (CMP, CBC, blood culture), IV hydration, broad-spectrum antibiotics for typical (pneumococcus, Staphylococcus aureus) and atypical (Mycoplasma pneumoniae) (CAP). (ceftriaxone, azithromycin) Ophthalmology should be consulted, and ICU monitoring may be necessary
synechiae
Adhesions of the iris to either the cornea or lens; complication of ocular trauma or inflammation of the iris; identified by ophthalmoscope or on slit-lamp examination
SCORTEN: Score of TEN
Scores the severity of bullous conditions; initially developed for TEN, but also utilized in patients with thermal burns or SJS
CU placement should be considered for any patient with a SCORTEN score 2 or greater.
SCORTEN
http://casefiles.mhmedical.com.mwu.idm.oclc.org/ViewLarge.aspx?figid=105347083&gbosContainerID=75&gbosid=219800
extent of epidermal detachment differentiates the SJS and TEN
SJS less than 10%, SJS/TEN overlap syndrome 10%-30%, TEN more than 30%
Common inciting agents of SJS/TEN
antibiotics (sulfonamides, PCN, cephs), NSAIDs, allopurinol, and antiepileptics (carbamazepine, phenytoin, lamotrigine, phenobarbital)
-first occur about 2 weeks after a new med exposure
increased risk for SJS in these pts
HIV: TMP-SMX
select human leucocyte antigen types (HLA-B 1502): aromatic anti epileptics (carbamazepine, phenytoin, and phenobarbital)
“slow acetylators”
polymorphism in IL-4 receptor gene
SJS prodrome
ever and flu-like illness, burning sensation or other skin paresthesias, erythroderma, tongue swelling, facial edema, and palpable purpura
SJS lesions
ill-defined or target-shaped erythematous macules with purpuric centers
symmetrical and typically begins on the face and thorax, before extending to other areas (palms and soles typically spared)